Home › Highland Therapeutics Announces Initiation Of Pivotal Trial Of HLD-200 In Pediatric ADHD Patients
 

Keywords :   


Highland Therapeutics Announces Initiation Of Pivotal Trial Of HLD-200 In Pediatric ADHD Patients

2015-08-05 07:56:18| drugdiscoveryonline Home Page

Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, recently announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), has initiated enrolment in a pivotal study to assess the safety and efficacy of HLD-200 – a next-generation formulation of methylphenidate – in children with Attention-Deficit/Hyperactivity Disorder (“ADHD”)

Tags: trial patients adhd announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.06Eastern North Pacific Tropical Weather Outlook
02.06Atlantic Tropical Weather Outlook
01.06Mining for Pearlizing Agent 
01.06The Power of Zinc Pyrithione
01.06Downward pH Drift
01.06Adding Fragrances to Hot Pours
01.06The Perils of Progress in the Search for New UV Filters
01.06This Interview Formality Jumpstarts Or Kills Your Chances Altogether
More »